Safety of switching directly from lamivudine to adefovir, versus overlapping lamivudine and adefovir followed by adefovir monotherapy, in patients with chronic hepatitis B.

Trial Profile

Safety of switching directly from lamivudine to adefovir, versus overlapping lamivudine and adefovir followed by adefovir monotherapy, in patients with chronic hepatitis B.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2011

At a glance

  • Drugs Adefovir (Primary) ; Lamivudine (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top